Additional file 1 of Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer

Additional file 1: Table S1. Clinical characteristics and molecular biomarkers at baseline in all enrolled patients. Table S2. Clinical characteristics and molecular biomarkers in patients with paired samples at baseline and after two treatment cycles. Table S3. The individual gene mutation list of all samples in this study. Table S4. Univariate COX analysis of biomarkers at baseline. Table S5. Gene mutations at baseline correlated with clinical outcomes of ICIs plus chemotherapy. Table S6. Comparison of clinical characteristics between patients with bITH-up and those with bITH-stable or down.

附加文件1：表S1 本研究入组全部患者的基线临床特征与分子生物标志物；表S2 存在基线与两次治疗周期后配对样本的患者的临床特征与分子生物标志物；表S3 本研究所有样本的个体基因突变列表；表S4 基线生物标志物的单因素COX分析；表S5 基线时与免疫检查点抑制剂（Immune Checkpoint Inhibitors，ICIs）联合化疗临床结局相关的基因突变；表S6 bITH升高患者与bITH稳定或降低患者的临床特征比较